# US 8,278,357 B2 · Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,357 B2
- Document ID: US8278357B2
- Status: Granted
- Kind: B2
- Application number: 12/591,090
- Filed: 2009-11-06
- Published: 2010-03-04
- Granted: 2012-10-02
- Earliest claimed: 2002-10-21
- Assignees: Ramot at Tel-Aviv University Ltd.
- Inventors: Bernard Attali; Asher Peretz
- Web page: https://patentgrep.com/patent/US8278357B2

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/195: having an amino group
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.

## Claims

### Claim 1

A method of modulating a voltage-dependent potassium channel, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a general Formula I:
wherein:
Z is an A-G(=K)—X—Y group,
and wherein:
A is alkyl or absent;
G is C;
K is selected from the group consisting of O and S;
X is selected from the group consisting of O and NRb; and
Y is selected from the group consisting of hydroxyalkyl and a polyalkylene glycol residue,
R1 is selected from the group consisting of hydrogen, alkyl, cycloalkyl or aryl;
each of R2, R3, R4, R5, R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, amino and —NR15R16, or, alternatively, at least two of R2, R3, R4, R5 and R6, of R7, R8, R9 and R10 form a five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
R15 and R16 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl and sulfonyl, or, alternatively R15 and R16 form a five- or six-member heteroalicyclic ring; and
Rb is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl,
wherein said modulating of said voltage-dependent potassium channel is for a treatment of a condition or disorder selected from the group consisting of epilepsy, and schizophrenia.

### Claim 2 (depends on 1)

The method of claim 1, wherein said polyalkylene glycol residue has a general formula III:
[(CH2)m-O]n-R17 Formula III
wherein:
each of m and n is independently an integer of 1-10; and
R17 is hydrogen, alkyl, cycloalkyl or aryl.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
K is O;
each of R2, R3, R4, R5 and R6 is independently selected from the group consisting of hydrogen, alkyl, halo and trihaloalkyl; and
each of R7, R8, R9 and R10 is hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said compound does not inhibit a cyclooxygenase activity.

### Claim 6 (depends on 5)

The method of claim 5, wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein said voltage-dependent potassium channel comprises a KCNQ2 channel and/or a KCNQ3 channel and/or a KCNQ2/3 channel.

### Claim 8 (depends on 1)

The method of claim 1, wherein said compound forms a part of a pharmaceutical composition which further includes a pharmaceutically acceptable carrier.

### Claim 9

A method of treating a neuropathic pain, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having general Formula I:
wherein:
Z is an A-G(=K)—X—Y group,
and wherein:
A is alkyl or absent;
G is selected from the group consisting of C, S and PRa;
K is selected from the group consisting of O and S;
X is selected from the group consisting of O, S and NRb or absent; and
Y is selected from the group consisting of hydroxyalkyl and a polyalkylene glycol residue,
R1 is selected from the group consisting of hydrogen, alkyl, cycloalkyl or aryl;
each of R2, R3, R4, R5, R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, amino and —NR15R16, or, alternatively, at least two of R2, R3, R4, R5 and R6, and/or of R7, R8, R9 and R10 form a five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
R15 and R16 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl and sulfonyl, or, alternatively R15 and R16 form a five- or six-member heteroalicyclic ring; and
each of Ra and Rb is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl.

### Claim 10 (depends on 9)

The method of claim 9, wherein said polyalkylene glycol residue has a general formula III:
[(CH2)m-O]n-R17 Formula III
wherein:
each of m and n is independently an integer of 1-10; and
R17 is hydrogen, alkyl, cycloalkyl or aryl.

### Claim 11 (depends on 9)

The method of claim 9, wherein:
G is C;
K is O;
each of R2, R3, R4, R5 and R6 is independently selected from the group consisting of hydrogen, alkyl, halo and trihaloalkyl; and
each of R7, R8, R9 and R10 is hydrogen.

### Claim 12 (depends on 9)

The method of claim 9, wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 9)

The method of claim 9, wherein said compound does not inhibit a cyclooxygenase activity.

### Claim 14 (depends on 13)

The method of claim 13, wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 15 (depends on 9)

The method of claim 9, wherein said compound forms a part of a pharmaceutical composition which further includes a pharmaceutically acceptable carrier.
